May 6, 2020
DongWha Pharm’s plans testing new drug candidate to treat COVID-19
DongWha Pharm’s said it is getting ready for second phase of clinical trials of new drug candidate DW2008 to treat COVID-19.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Asia
April 24, 2020
– BIO KOREA 2020 International convention virtual
CHEONGJU, South Korea–(BUSINESS WIRE)–#BIOKOREA—BIO KOREA 2020 International Convention, where global bio experts correspond, is shifting to an online-only event.
April 24, 2020
Positive outcome from study for Chugai’s satralizumab
Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added to baseline immunosuppressant therapy.
March 18, 2020
Yokogawa Releases SU10 Single Cellome Unit for Use in Biological Research
Yokogawa has developed the SU10 Single CellomeTM Unit, a device that uses a nanopipette*1 to inject substances such as genes and drugs and aspirate intracellular materials at target locations in individual cells
March 18, 2020
The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate
– Results published in first paper from 18-month analysis of ongoing pivotal Phase 3 trial were generally consistent with overall…
March 16, 2020
BioNTech, Fosun Pharma, Pfizer working on COVID-19 vaccine. Clinical testing in Germany in April
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
March 15, 2020
WHO: How to control and prevent COVID-19 in schools
The World Health Organisation has issued a guideline to keep safety in schools. We have outlined the most important keys…
December 20, 2019
Hutschison China MediTech get’s priority review status for its anti-cancer drug surufatinib
Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).
November 28, 2019
ViGeneron closes Series A round which attracts WuXi AppTec and Sequoia Capital China
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.
October 30, 2019
Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019.